Clinical use of crizotinib for the treatment of non-small cell lung cancer

Patrick J Roberts Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Absract: Discoveries over the last decade have fundamentally transformed the way we define lung cancer. Gone are the days of the simple binary classification system of non-smal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Roberts PJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8dd0707422e54eee911749e60871090e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8dd0707422e54eee911749e60871090e
record_format	dspace
spelling	oai:doaj.org-article:8dd0707422e54eee911749e60871090e2021-12-02T03:11:45ZClinical use of crizotinib for the treatment of non-small cell lung cancer1177-54751177-5491https://doaj.org/article/8dd0707422e54eee911749e60871090e2013-04-01T00:00:00Zhttp://www.dovepress.com/clinical-use-of-crizotinib-for-the-treatment-of-non-small-cell-lung-ca-a12876https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Patrick J Roberts Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Absract: Discoveries over the last decade have fundamentally transformed the way we define lung cancer. Gone are the days of the simple binary classification system of non-small cell lung cancer (NSCLC) and small cell lung cancer. Today, accurate identification of the histological and molecular subtype of NSCLC is required for selecting standard cytotoxic chemotherapy and targeted therapies. The identification of anaplastic lymphoma kinase (ALK) rearrangements in 5-7% of NSCLC patients and the rapid clinical development of crizotinib for these patients is the most recent clinical example necessitating the proper identification of the molecular characteristics of NSCLC for treatment decisions. The discovery of ALK rearrangements in NSCLC serendipitously coincided with the development of crizotinib for other ALK or MET driven malignancies. The clinical development of crizotinib for ALK-positive NSCLC patients has been an amazing success story of translational medicine that relied on the prior clinical experience of other targeted predecessors (i.e. erlotinib in EGFR mutant NSCLC) and a compound ready for clinical development to gain expedited FDA approval. This review discusses the clinical development and use of crizotinib in NSCLC. Keywords: Xalkori, Non-Small Cell Lung Cancer, ALK, EML4-ALK, HSP90 inhibitors, ROS1, METRoberts PJDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 91-101 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Roberts PJ Clinical use of crizotinib for the treatment of non-small cell lung cancer
description	Patrick J Roberts Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Absract: Discoveries over the last decade have fundamentally transformed the way we define lung cancer. Gone are the days of the simple binary classification system of non-small cell lung cancer (NSCLC) and small cell lung cancer. Today, accurate identification of the histological and molecular subtype of NSCLC is required for selecting standard cytotoxic chemotherapy and targeted therapies. The identification of anaplastic lymphoma kinase (ALK) rearrangements in 5-7% of NSCLC patients and the rapid clinical development of crizotinib for these patients is the most recent clinical example necessitating the proper identification of the molecular characteristics of NSCLC for treatment decisions. The discovery of ALK rearrangements in NSCLC serendipitously coincided with the development of crizotinib for other ALK or MET driven malignancies. The clinical development of crizotinib for ALK-positive NSCLC patients has been an amazing success story of translational medicine that relied on the prior clinical experience of other targeted predecessors (i.e. erlotinib in EGFR mutant NSCLC) and a compound ready for clinical development to gain expedited FDA approval. This review discusses the clinical development and use of crizotinib in NSCLC. Keywords: Xalkori, Non-Small Cell Lung Cancer, ALK, EML4-ALK, HSP90 inhibitors, ROS1, MET
format	article
author	Roberts PJ
author_facet	Roberts PJ
author_sort	Roberts PJ
title	Clinical use of crizotinib for the treatment of non-small cell lung cancer
title_short	Clinical use of crizotinib for the treatment of non-small cell lung cancer
title_full	Clinical use of crizotinib for the treatment of non-small cell lung cancer
title_fullStr	Clinical use of crizotinib for the treatment of non-small cell lung cancer
title_full_unstemmed	Clinical use of crizotinib for the treatment of non-small cell lung cancer
title_sort	clinical use of crizotinib for the treatment of non-small cell lung cancer
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/8dd0707422e54eee911749e60871090e
work_keys_str_mv	AT robertspj clinicaluseofcrizotinibforthetreatmentofnonsmallcelllungcancer
_version_	1718401869986922496

Clinical use of crizotinib for the treatment of non-small cell lung cancer

Ejemplares similares